Search

everythinglearnresearchcommunity

for

Search:↓

PKC ε increases hair follicle stem cell turnover and may raise skin cancer risk.

JAK inhibitors effectively and safely treat alopecia areata with few serious side effects.

Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

Diphencyprone initially increases mouse hair growth, then slows it, possibly due to changes in specific protein levels.

JAK inhibitors help with skin conditions but need more research on dosing and safety.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.

Eph receptors and ephrins may be promising targets for treating diseases, but more understanding is needed for effective and safe therapies.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

VEGF stimulates hair cell growth and increases growth receptor levels through a specific signaling pathway.

DHT affects bone growth by altering gene activity in osteoblasts, potentially complicating steroid use.

FGF9 controls which receptors it binds to through a process where two FGF9 molecules join, and changes in FGF9 can lead to incorrect receptor activation.

The vitamin D receptor is involved in multiple body functions beyond calcium regulation, including immune response and rapid reactions not related to gene activity.

A certain smell receptor in hair follicles can affect hair growth when activated by a synthetic sandalwood scent.

Janus kinase inhibitors are promising drugs for treating autoimmune and inflammatory diseases.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Applying a specific inhibitor lightens skin and hair color.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.

NcoA4 may have roles beyond helping control gene activity, possibly affecting cell behavior and stability.

Many patients on new leukemia drugs had mild to moderate skin reactions.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

PGD2 increases androgen receptor activity in hair cells, which could be targeted to treat hair loss.

A gene called Gk5 controls lipid production in the skin and affects hair growth.

Researchers created immortal human skin cells with constant testosterone receptor activity to study hair loss and test treatments.

Certain Dibenzo derivatives may help treat prostate cancer.

Rapamycin may help treat Leigh syndrome by targeting protein kinase C.

CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.

New treatment with green tea polyphenols and nicotinamide improves skin problems from cancer therapy.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.